Insider Selling: Astera Labs (NASDAQ:ALAB) General Counsel Sells 10,000 Shares of Stock

Key Points

• Astera Labs' General Counsel, Philip Mazzara, sold 10,000 shares of stock on October 1st for approximately $1.92 million, reducing his ownership by 6.19%.
• The company's stock price recently dropped 4.2%, closing at $200.74, amid high trading volume of over 5 million shares.
• Astera Labs reported a 149.5% increase in quarterly revenue year-over-year, with an EPS of $0.44 exceeding analyst expectations of $0.33.

Astera Labs, Inc. (NASDAQ:ALAB - Get Free Report) General Counsel Philip Mazzara sold 10,000 shares of Astera Labs stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $192.16, for a total transaction of $1,921,600.00. Following the completion of the transaction, the general counsel owned 151,573 shares in the company, valued at $29,126,267.68. This trade represents a 6.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Philip Mazzara also recently made the following trade(s):

• On Thursday, August 28th, Philip Mazzara sold 10,000 shares of Astera Labs stock. The stock was sold at an average price of $188.70, for a total transaction of $1,887,000.00.
• On Monday, August 18th, Philip Mazzara sold 7,237 shares of Astera Labs stock. The stock was sold at an average price of $183.51, for a total transaction of $1,328,061.87.

Astera Labs Trading Down 4.2%

ALAB traded down $8.86 during trading on Friday, hitting $200.74. The stock had a trading volume of 5,183,840 shares, compared to its average volume of 5,124,385. The firm has a market cap of $33.37 billion, a PE ratio of 358.46, a P/E/G ratio of 4.93 and a beta of 1.43. Astera Labs, Inc. has a 12 month low of $47.13 and a 12 month high of $262.90. The company has a 50 day simple moving average of $188.26 and a 200-day simple moving average of $118.24.

Astera Labs (NASDAQ:ALAB - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.33 by $0.11. The firm had revenue of $191.93 million for the quarter, compared to the consensus estimate of $172.46 million. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The business's quarterly revenue was up 149.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.13 EPS. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, sell-side analysts anticipate that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on ALAB. Wall Street Zen upgraded shares of Astera Labs from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Morgan Stanley raised their price target on shares of Astera Labs from $155.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, August 29th. Northland Capmk lowered shares of Astera Labs from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 22nd. Needham & Company LLC raised their price target on shares of Astera Labs from $100.00 to $170.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Astera Labs in a research report on Saturday, September 27th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $159.83.

Hedge Funds Weigh In On Astera Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALAB. Oliver Lagore Vanvalin Investment Group acquired a new position in Astera Labs in the second quarter valued at about $29,000. Bernard Wealth Management Corp. acquired a new position in Astera Labs in the second quarter valued at about $36,000. Clearstead Trust LLC boosted its position in Astera Labs by 46,100.0% in the second quarter. Clearstead Trust LLC now owns 462 shares of the company's stock valued at $42,000 after buying an additional 461 shares in the last quarter. Advisors Asset Management Inc. boosted its position in Astera Labs by 68.6% in the second quarter. Advisors Asset Management Inc. now owns 477 shares of the company's stock valued at $43,000 after buying an additional 194 shares in the last quarter. Finally, Manchester Capital Management LLC boosted its position in Astera Labs by 141.5% in the second quarter. Manchester Capital Management LLC now owns 483 shares of the company's stock valued at $44,000 after buying an additional 283 shares in the last quarter. 60.47% of the stock is currently owned by institutional investors and hedge funds.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.